Hamilton Morris Synthesizes 5-MeO-DMT in “Pharmacopeia”
“I believe one person can produce enough 5-MeO-DMT to supply everyone that would ever want it.”
Industry
Catching Up with the Psychedelic Entourage Effect: Part 2 – Mydecine Innovations Group
“Our researchers will isolate and study all of the potentially ‘magic’ molecules in mushrooms.”
Catching Up With the Psychedelic Entourage Effect-Part 1: How We Got Here
The entourage effect caught PSR’s eye back in early 2019. What are experts saying about the theory now and how are psychedelic research companies approaching it?
Numinus Legally Cultivates Magic Mushrooms Under License from Health Canada
This is the first time since the 1970s that a Canadian company has legally cultivated and harvested psychedelic mushrooms.
UNC to Receive $26.9M from DARPA to Develop Psychiatric Medicines
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
CaaMTech Partners with the National Institutes of Health to Study Synthetic Tryptamines
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
Stopping Bad LSD Trips with “Off-Switch” Technology
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
UK Assessment Agency Rejects Spravato Ketamine Nasal Spray
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
COMPASS Patent Highlights Importance of Crystallography in Psychedelic Drug Development
The scope and validity of this patent will depend on how x-ray diffraction data is interpreted.
Machine Intervention: Psychedelics, Artificial Intelligence, and the Drug Discovery Process
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare